The Pharmacology of Acute Lung Injury in Sepsis

Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pat...

Descripción completa

Detalles Bibliográficos
Autor principal: Varisco, Brian Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130333/
https://www.ncbi.nlm.nih.gov/pubmed/21738527
http://dx.doi.org/10.1155/2011/254619
_version_ 1782207605084520448
author Varisco, Brian Michael
author_facet Varisco, Brian Michael
author_sort Varisco, Brian Michael
collection PubMed
description Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pathophysiology of ALI, commonly employed pharmacologic and nonpharmacologic treatments, and innovative therapeutic modalities that will likely be the focus of future trials.
format Online
Article
Text
id pubmed-3130333
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31303332011-07-07 The Pharmacology of Acute Lung Injury in Sepsis Varisco, Brian Michael Adv Pharmacol Sci Review Article Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneficial. In this paper, we discuss the epidemiology and pathophysiology of ALI, commonly employed pharmacologic and nonpharmacologic treatments, and innovative therapeutic modalities that will likely be the focus of future trials. Hindawi Publishing Corporation 2011 2011-06-28 /pmc/articles/PMC3130333/ /pubmed/21738527 http://dx.doi.org/10.1155/2011/254619 Text en Copyright © 2011 Brian Michael Varisco. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Varisco, Brian Michael
The Pharmacology of Acute Lung Injury in Sepsis
title The Pharmacology of Acute Lung Injury in Sepsis
title_full The Pharmacology of Acute Lung Injury in Sepsis
title_fullStr The Pharmacology of Acute Lung Injury in Sepsis
title_full_unstemmed The Pharmacology of Acute Lung Injury in Sepsis
title_short The Pharmacology of Acute Lung Injury in Sepsis
title_sort pharmacology of acute lung injury in sepsis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130333/
https://www.ncbi.nlm.nih.gov/pubmed/21738527
http://dx.doi.org/10.1155/2011/254619
work_keys_str_mv AT variscobrianmichael thepharmacologyofacutelunginjuryinsepsis
AT variscobrianmichael pharmacologyofacutelunginjuryinsepsis

Ejemplares similares